12th Annual Guidelines for Disseminating Off-Label Information

Program Highlights

• Learn about liability under RICO -- Understand the recent verdict against Pfizer related to off-label promotion of Neurontin
• Understand how efforts arising under HEAT at DOJ, HHS, OIG and FDA impact criminal investigations and civil False Claims Act cases
• Assess the high-risk areas for off-label requests and strengthen the role of the MSL in the exchange of scientific information
• Link Rx and ICD-9 data with longitudinal data to identify off-label prescribing patterns
• Identify trends in allegations, fines and penalties and newly required compliance obligations
• Hear directly from the Chief Compliance Officer at InterMune on the settlement with the DOJ and how they are operating under a CIA with the OIG
• Participate in a panel discussion that brings together all key stakeholders in an off-label case and plays out a hypothetical scenario